Page 1

SYNLABY Press release Munich , 10 November 2021 SYNLAB delivers strong 9M 2021 results , on track to significantly exceed 2021 financial targets set at IPO ● ● ● Strong revenue growth delivered since the beginning of the year + 20 % revenue growth in Q3 2021 + 64 % in 9M 2021 Profitability uplift driven by volume leverage O Q3 2021 margin remained elevated post H1 2021 peak O 32.8 % adjusted EBITDA margin in 9M 2021 Extra cash generation with capacity to accelerate growth plans O EUR 630 million unlevered free cash flow in 9M 2021 Leverage ratio at 1.3x by end of September O 18 acquisitions completed ; full - year M & A target spend of EUR 200 million already exceeded 2021 financial guidance ( adjusted slightly upward today ) materially higher than IPO targets 2022 outlook showing further material upside vs. pre COVID - 19 period ( + 50 % revenue vs. 2019 ) SYNLAB , ( ISIN : DE000A2TSL71 , SYMBOL : SYAB ) the largest European clinical laboratory and medical diagnostic services company , announces its unaudited consolidated Q3 / 9M results . ● + 3.5 % underlying growth in 9M 2021 driven by For You initiatives " At the end of the third quarter of 2021 , our results are already significantly above the results for the full year 2020. We are therefore in a position to significantly exceed the 2021 targets set at IPO . This major outperformance is driven by consistent execution of our growth agenda . We are progressing on our " For You " growth initiatives , notably around retail and prescribers . We have made further inroads into the hospital market thanks to our leadership position in Specialty testing . And we have accelerated on our M & A roadmap . Meanwhile , the COVID - 19 activity is reducing from peak levels but remains at elevated levels , thanks to our unmatched geographic breadth . In addition to giving us significantly increased financial capacity to accelerate our development , this very strong start as a public company evidences our strong execution and transformation capabilities for the future . " says Mathieu Floreani , CEO of SYNLAB Group . SYNLAB Key figures ( € m ) Revenue Operating profit Net profit ( Group share ) Adjusted EBITDA Adjusted operating profit ( AOP ) Adjusted net profit ( Group share ) Unlevered free cash flow Q3 2021 849.3 173.8 128.0 245.3 192.1 143.3 202 YOY Growth + 20 % x21.5 + 200m SYNLAB AG Moosacher Str . 88 80809 Munich Germany x1.3 x1.3 + 83m + 151m 9M 2021 2,772.3 689.1 471.3 908.0 761.4 514.9 630.2 YoY Growth + 64 % x8.6 + 565m x2.4 x3.0 + 447m + 570m 1